© 2023 MJH Life Sciences™ and Infection Control Today. All rights reserved.
A complication of measles that kills children years after they have the infection is more common than thought, according to a study being presented at IDWeek 2016™. The research underscores the vital importance of herd immunity by vaccination: All who are eligible should be vaccinated to protect those who can’t be immunized, including infants.
Subacute sclerosing panencephalitis (SSPE) is a neurological disorder that is 100 percent fatal. Infants younger than 12 months, who are too young to receive measles, mumps and rubella (MMR) vaccine, can get infected with measles and later develop SSPE, which may lay dormant for years. While it was once thought the risk of post-measles SSPE was one in 100,000, recent research identified a rate as low as 1 in 1,700 in Germany among children infected with measles before they were 5 years old, and the new study found it is about one in 600 for those who get measles as infants before being vaccinated.
There is no cure for SSPE and the only way to prevent it is to vaccinate everyone against measles.
“This is really alarming and shows that vaccination truly is life-saving,” said James D. Cherry, MD, MSc, an author of the study, and a distinguished research professor of pediatrics and infectious diseases at the David Geffen School of Medicine at the University of California Los Angeles. “Measles is a disease that could be eliminated worldwide, but that means vaccinating at least 95 percent of all who are eligible with two doses of measles vaccine in order to protect everyone, including those who aren’t old enough to get the vaccine.”
Researchers identified 17 cases of SSPE in California between 1998 and 2015, all of whom had measles prior to being vaccinated. Although all got measles as children, SSPE did not develop right away: The average age at diagnosis was 12, but the range was from 3 to 35 years old. In a sub-analysis of California children who got measles while living in the United States, 1 in 1,387 who got it younger than 5 years and 1 in 609 who got it younger than 12 months developed SSPE. Many of these patients had ongoing cognitive or movement problems before they were definitively diagnosed. A majority of the children (67 percent) were living in the United States when they got measles.
Measles infection causes fever, runny nose, cough, red eyes, sore throat and rash. The virus spreads throughout the body and is cleared within 14 days. In rare cases the virus spreads to the brain, but then becomes dormant. Eventually it can lead to SSPE, resulting in deterioration and death. Researchers don’t know what causes the virus to reactivate.
Vaccinating a very high portion of the population ensures herd immunity, meaning even those who can’t be vaccinated are protected because the disease is less likely to spread. The MMR vaccine isn’t recommended until infants are 12 months old because they retain some of their mother’s antibodies until that age, making the vaccine less effective, but leaving them vulnerable to measles. Others who can’t get vaccinated include those with immune system disorders.
The first dose of MMR is given between 12 and 15 months old. Because there is a 5 percent vaccination failure rate, a second dose is given to children before they begin school. Measles is so contagious that 95 percent of people need to be vaccinated with two doses to protect those who aren’t, said Cherry. Therefore, all who are eligible – including adults who had not previously been vaccinated – should receive two doses of the vaccine. Nearly 92 percent of U.S. children 19-35 months old have received the MMR vaccine, according to the CDC.
“Parents of infants who have not yet been vaccinated should avoid putting their children at risk,” said Cherry. “For example, they should postpone trips overseas – including to Europe – where measles is endemic and epidemic until after their baby has been vaccinated with two doses. It’s just not worth the risk.”
The lead author of the study is Kristen Wendorf, MD, MS. The co-authors are Kathleen Winter, MPH, PhD,